NASDAQ: CUE · Life Sciences · 5 alerts · CIK 1645460
Share price
$14.10Close, Nov 16
Market cap
$102M
Shares outstanding
7.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cue Biopharma, Inc. filings on SEC EDGAR ↗
Cue Biopharma reported third quarter 2026 financial results and highlighted the initiation of first-in-human dosing for CUE-401, its first autoimmune therapeutic candidate. The company also shared positive Phase 2 findings for CUE-221 in chronic spontaneous urticaria (CSU), demonstrating statistically significant hives resolution and potential differentiation from existing therapies like Xolair.
Term
Q3 2026
“We are seeing exciting momentum across our portfolio. We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy.”
Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma
“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience.”
Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma
Cue Biopharma Chief Legal Compliance Officer Sumita Ray Sells $51.7K of Stock
Sumita Ray, Chief Legal Compliance Officer, sold 1,844 shares of Cue Biopharma, Inc. at $28.05 a share, worth $51.7K in total on Oct 12, 2026. Shares held after the trade: 116,701 (-1.6%).
Cue Biopharma VP, Prin. Accounting Officer Michael Vincent Meluzio Sells $32.1K of Stock
Michael Vincent Meluzio, VP, Prin. Accounting Officer, sold 1,144 shares of Cue Biopharma, Inc. at $28.05 a share, worth $32.1K in total on Oct 12, 2026. Shares held after the trade: 47,817 (-2.3%).
Cue Biopharma CEO Shao-Lee Lin Sells $305K of Stock
Shao-Lee Lin, CEO, sold 11,087 shares of Cue Biopharma, Inc. at $27.50 to $28.05 a share (average $27.55) in 2 transactions, worth $305K in total on Oct 12, 2026. Shares held after the trade: 694,908 (-0.2%).
Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in patients with moderate to severe Chronic Spontaneous Urticaria (CSU). The study met its primary endpoint of complete resolution of hives (HSS7=0) at all dose levels with high statistical significance, demonstrating superiority over placebo and showing a favorable safety profile. The company plans to advance the candidate into a Phase 2b/3 registration-enabling study based on these results.